ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "T cells"

  • Abstract Number: 2816 • 2019 ACR/ARP Annual Meeting

    An Expanded Granzyme K+ CD8 T Cell Population Induces Inflammatory Responses in Rheumatoid Arthritis Synovium

    Anna Helena Jonsson1, Fan Zhang 2, Gerald Watts 2, Kevin Wei 1, Deepak Rao 2, Soumya Raychaudhuri 2 and Michael Brenner 3, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women’s Hospital:, Boston

    Background/Purpose: CD8 T cells represent nearly half of T cells in inflamed synovium from patients with rheumatoid arthritis (RA). Research to date has focused on…
  • Abstract Number: 111 • 2019 ACR/ARP Annual Meeting

    The Transcription Factor STAT3 Regulates Pathogenic Th17 Responses in Autoimmune Disease via Noncanonical Roles

    Catherine Poholek1, Itay Raphael 2 and Mandy McGeachy 2, 1UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: The Th17 lineage of CD4 T cells drives autoimmune diseases such as RA, SLE, IBD, and MS. The JAK2/STAT3 signaling pathway is required for…
  • Abstract Number: 2818 • 2019 ACR/ARP Annual Meeting

    Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis

    Virginia Muir 1, Cliff Rims 1, Kevin Deane 2, Jeffrey Carlin 3, Sylvia Posso 1, Sunil Nagpal 4, Navin Rao 4, Frédéric Baribaud 5, George Vratsanos 6, William Robinson 7, Gary Firestein 8, V. Michael Holers 9, Peter Linsley 1, Eddie James1 and Jane Buckner 1, 1Benaroya Research Institute, Seattle, WA, 2University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, 3Virginia Mason Medical Center, Seattle, WA, 4Janssen R&D, Spring House, PA, 5Janssen Research & Development, LLC, Spring House, PA, 6JNJ, Raritan, NJ, 7Stanford University, Palo Alto, CA, 8University of California, San Diego, San Diego, 9University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver

    Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated…
  • Abstract Number: 38 • 2018 ACR/ARHP Annual Meeting

    Pre-Clinical Clonally-Expanded aggrecan89-103–Specific CD4+ T Cells Are a Target for Autoimmune Arthritis Prevention

    Pascale Wehr1, Hendrik Nel1, Soi Cheng Law1, Diahann Jansen1, Nicole La Gruta2, Hugh Reid2, Jamie Rossjohn2 and Ranjeny Thomas1, 1University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, Australia, 2Infection and Immunity Program, Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia

    Background/Purpose: In the pre-clinical rheumatoid arthritis (RA) prodrome, autoantibodies and transient symptoms may develop. Pre-clinical autoantibody development suggests concomitant expansion of autoantigen-specific CD4+ follicular helper…
  • Abstract Number: 147 • 2018 ACR/ARHP Annual Meeting

    T Follicular Helper Cell Phenotype in RA Patients Receiving Rituximab

    Betty Hsiao1, Jin-Young Choi2 and Joseph E. Craft3, 1Yale University School of Medicine, New Haven, CT, 2Section of Rheumatology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 3Department of Internal Medicine/Rheumatology, Yale University School of Medicine, New Haven, CT

    Background/Purpose: B and T cells contribute to tissue injury in rheumatoid arthritis (RA). Rituximab (RTX), an anti-CD20 monoclonal antibody, is used for the treatment of…
  • Abstract Number: 1091 • 2018 ACR/ARHP Annual Meeting

    Serine Arginine-Rich Splicing Factor 1 (SRSF1) Is Essential for T Lymphocyte Homeostasis and Decreased Levels of SRSF1 Correlate with Lymphopenia in SLE Patients

    Takayuki Katsuyama1, Kotaro Iida2 and Vaishali R. Moulton1, 1Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 2Beth Israel Deaconess Medical Center, Harvard Medical School, Division of Rheumatology, Department of Medicine, Boston, MA

    Background/Purpose: Lymphopenia is one of the most common clinical features in patients with systemic lupus erythematosus (SLE), and associates with severe disease and comorbidities such…
  • Abstract Number: 2233 • 2018 ACR/ARHP Annual Meeting

    Activation and Deficiency of Circulating Mucosal-Associated Invariant T Cells in Patients with Gouty Arthritis

    Yong-Wook Park1, Young-Nan Cho2, Hye-Mi Jin1 and Seung-Jung Kee3, 1Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South), 2Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, MN, Korea, Republic of (South), 3Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South)

    Background/Purpose: Mucosal-associated invariant T (MAIT) cells contribute to protection against certain microorganism infections and play an important role in mucosal immunity. Upon antigen recognition, MAIT…
  • Abstract Number: 39 • 2018 ACR/ARHP Annual Meeting

    Allogeneic Mesenchymal Stem Cells Derived Extracellular Vesicles As a Superior Immunosuppressant in Murine Arthritis Therapy

    Runci Wang1,2, Yi Liu3,4 and Songtao Shi5, 1Department of Anatomy and cell biology, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, 2Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China, 3Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Chengdu, China, 4Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, China, 5Department of Anatomy and Cell Biology, School of Dental Medicine, University of Pennsylvania,, Philadelphia, PA

    Allogeneic mesenchymal stem cells derived extracellular vesicles as a superior immunosuppressant in murine arthritis therapyRunci Wang1,2, Yi Liu2, Songtao Shi1Affiliation: 1. Department of Anatomy and…
  • Abstract Number: 151 • 2018 ACR/ARHP Annual Meeting

    Molecular Mechanisms of Pathogenic T Cell Resilience in Human Arthritis

    Pavanish Kumar1, Jing Yao Leong1, Bhairav Paleja1, Suzan Saidin1, jorg van Loosdregt1, Thaschawee Arkachaisri2, Alessandro Consolaro3, Marco Gattorno4, Alberto Martini5, Gary W Williams6, Ken D Pischel6, Martin Lotz7 and Salvatore Albani8, 1Translational Immunology Institute, Singhealth/Duke-NUS Academic Medical Centre, Singapore, Singapore, 2KK Women's and Children's Hospital, Singapore, Singapore, 3Second Paediatric Division, University of Genoa and G Gaslini Institute, Genova, Italy, Genova, Italy, 4Second Paediatric Division, University of Genoa and G Gaslini Institute, Genova, Italy, Genoa, Italy, 5Pediatric Rheumatology International Trial Organization (PRINTO) Coordinating Centre, Genoa, Italy, 6Scripps Clinic, La Jolla,, California, CA, 7Department of Molecular & Experience Medicine, Scripps Research Institute, LaJolla, CA, 8Translational Immunology Institute, Singhealth/Duke-NUS Acedemic Medical Centre, Singapore, Singapore

    Background/Purpose: T-cell resilience is critical to the immune pathogenesis of human autoimmune arthritis. Autophagy is essential for memory T cell generation and is associated with…
  • Abstract Number: 1583 • 2018 ACR/ARHP Annual Meeting

    Low-Dose IL-2 Promotes the Proliferation of Peripheral Regulatory T Cells in Primary Sjogren’s Syndrome to Restore Its Balances with Pro-Inflammatory Lymphocytes

    Miao Miao1, Zhenye Hao1, Yingying Guo1, Xiaoying Zhang1, Sheng-Xiao Zhang1, Jing Luo2, Jinfang Zhao3, Chong Gao4 and Xiao-Feng Li5, 1The Second Hospital of Shanxi Medical University, Taiyuan, China, 2the Second Hospital of Shanxi Medical University, Taiyuan, China, 3The Shanxi Medical University, Taiyuan, China, 4Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, 5Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China

    Background/Purpose: To investigate the effect of low-dose IL-2 on the balance of Treg with Teff and other pro-inflammatory lymphocytes in peripheral blood of pSS patients.Methods:…
  • Abstract Number: 2795 • 2018 ACR/ARHP Annual Meeting

    IL-23 Acts through IL-23R+ Tfh cells to Promote Pathogenic IgG Autoantibody Formation in Lupus

    Huixian Hong1, Qi Wu2, PingAr Yang2, Bao Luo3, Jun Li4, Hao Li5, Daniel Cua6, Hui-Chen Hsu2 and John D. Mountz7, 1University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 2Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 3DIvision of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, 5Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 6Discovery Research, Merck Research Laboratory, Palo Alto, CA, 7University of Alabama at Birmingham, Devision of Clinical Immunology and Rheumatology; University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL

    Background/Purpose: IL-23 is currently a target for several forms of autoimmune diseases, yet its role in promoting pathogenic autoantibody development is less clear. IL-23 was…
  • Abstract Number: 44 • 2018 ACR/ARHP Annual Meeting

    Histone Deacetylase 1 (HDAC1): A Novel Therapeutic Target in Patients with Rheumatoid Arthritis

    Lisa Goschl1, Victoria Saferding2, Johan Bäcklund3, Clemens Scheinecker4, Josef S. Smolen5, Günter Steiner6, Wilfried Ellmeier1 and Michael Bonelli7, 1Medical University of Vienna,Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria, 2Medical University of Vienna, Austria, Vienna, Austria, 3Karolinska Institute,Department of Medical Biochemistry and Biophysics, Stockholm, Sweden, 4Medical University of Vienna, Divison of Rheumatology, Vienna, Austria, 5Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 6Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Austria, Vienna, Austria, 7Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria

    Background/Purpose: Despite enormous efforts to develop new therapeutic strategies for treatment of rheumatoid arthritis (RA), the large number of non responding patients to currently available…
  • Abstract Number: 153 • 2018 ACR/ARHP Annual Meeting

    Chemotaxis of Vδ2 T Cells to the Joints Contributes to the Pathogenesis of Rheumatoid Arthritis

    Xiao Xinyue1, Wenxiu MO2 and Xuan Zhang3, 1Peking Union Medical College Hospital, Beijing, China, 2Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, 3Rheumatology, Peking Union Medical College Hospital, Beijing, China

    Background/Purpose: To explore the role of Vδ2 t cells in the pathogenesis of rheumatoid arthritis (rA) Methods: Sixty-eight patients with RA, 21 patients with osteoarthritis…
  • Abstract Number: 1587 • 2018 ACR/ARHP Annual Meeting

    Pathogenic Role of Interleukin 27 in the Nonobese Diabetic Mouse Model of Sjögren Syndrome

    Scott Lieberman1, Jennifer Barr2, Xiaofang Wang2 and Yi-Guang Chen3, 1Division of Rheumatology, Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA, 2Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA, 3Pediatrics, Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Sjögren syndrome is an immunologically complex autoimmune disease characteristically targeting the lacrimal and salivary glands leading to progressively worsening oral and ocular health and…
  • Abstract Number: 2797 • 2018 ACR/ARHP Annual Meeting

    Regulation of Autoimmune T Cells By the Co-Receptors CD28 and PD-1

    Sabina Sandigursky1 and Adam Mor2, 1Medicine, NYU School of Medicine, New York, NY, 2Rheumatology and Pathology, NYU School of Medicine, New York, NY

    Background/Purpose: T cells play a major role in the pathogenesis of Rheumatoid Arthritis (RA). These cells are regulated by signals provided via the T cell…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology